These results could be due to differences in altered expression of the HLA class II master regulatory gene, class II transactivator (CIITA), which also governs HLA-DM and invariant chain (Ii) expression, and are also altered in prostate cancer cells [36]. This evidence concerns the gene CIITA and Familial prostate cancer.